Cargando…
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
BACKGROUND & AIMS: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed b...
Ejemplares similares
-
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
por: Corominas, Josep, et al.
Publicado: (2021) -
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
por: Sapena, Víctor, et al.
Publicado: (2022) -
Controversies in the management of hepatocellular carcinoma
por: Forner, Alejandro, et al.
Publicado: (2019) -
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction
por: Muñoz-Martínez, Sergio, et al.
Publicado: (2023) -
Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs
por: Díaz‐González, Álvaro, et al.
Publicado: (2021)